



UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED 31ST MARCH, 2011

| S. No. | PARTICULARS | Amount (Rs. In Million) | | | |
|--------|---|-------------------------|-------------------------|-------------------------|-----------------------|
| | | Quarter Ended on | | Year Ended on | |
| | | 31-03-2011 Unaudited | 31-03-2010 Unaudited | 31-03-2011 Unaudited | 31-03-2010 Audited |
| 1 | Net Sales/ Income from operations | 964.62 | 807.83 | 3572.73 | 3,119.30 |
| 2 | Other Income | 0.98 | 3.80 | 2.96 | 1.16 |
| | Total Income | 965.60 | 811.63 | 3,575.69 | 3,120.46 |
| 3 | Total Expenditure : | | | | |
| | (a) (Increase)/ Decrease in stock in trade | -48.48 | -10.38 | -39.03 | -61.86 |
| | (b) Consumption of raw materials | 570.02 | 462.87 | 1998.59 | 1,883.87 |
| | (c) Staff Cost | 56.63 | 39.94 | 194.51 | 179.15 |
| | (d) Other expenditure | 140.07 | 129.72 | 527.28 | 373.34 |
| | Total | 718.24 | 622.15 | 2,681.35 | 2,374.49 |
| | EBDIT | 247.36 | 189.48 | 894.34 | 745.97 |
| 4 | Interest & Bank Charges | 52.88 | 29.97 | 185.33 | 139.55 |
| 5 | Depreciation | 25.26 | 5.86 | 96.25 | 116.87 |
| 6 | Profit/ (Loss) before tax (1+2-3-4-5) | 169.22 | 153.65 | 612.76 | 489.54 |
| 7 | Provision for Taxation | 33.73 | 26.11 | 122.13 | 79.05 |
| 8 | Net Profit/ (Loss) (6-7) | 135.49 | 127.54 | 490.63 | 410.49 |
| 9 | Paid up Equity Share Capital | 91.29 | 84.73 | 91.29 | 84.73 |
| 10 | Reserves excluding revaluation reserves | N. A. | N. A. | N.A | 1,714.73 |
| 11 | E.P.S - Basic not annualised for the qtr | 14.84 | 15.05 | 53.74 | 48.45 |
| | - Annualised | 59.37 | 60.21 | 53.74 | 48.45 |
| 12 | Public Shareholding | | | | |
| | - Number of Shares | 6376092 | 6320089 | 6376092 | 6320089 |
| | Percentage of Shareholding | 69.04 | 74.59 | 69.04 | 74.59 |
| 13 | Promoters and promoter group shareholding | | | | |
| | a) Plodged as collateral security to bank | | | | |
| | - Number of Shares | 1930000 | 1870000 | 1930000 | 1870000 |
| | - Percentage of shares (as a % of the total share holding of promoter and promoter group) | 70.10 | 86.86 | 70.10 | 86.86 |
| | - Percentage of shares (as a % of the total share capital) | 21.14 | 22.07 | 21.14 | 22.07 |
| | b) Non-Encumbered | | | | |
| | - Number of Shares | 823002 | 283002 | 823002 | 283002 |
| | Percentage of shares (as a % of the total share holding of promoter and promoter group) | 20.80 | 12.14 | 20.80 | 12.14 |
| | - Percentage of shares (as a % of the total share capital) | 09.01 | 03.34 | 09.01 | 03.34 |

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase-I,
Panchkula (Hry.) 134113, India

Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com



For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-5933094, 5933090, 5933377, Fax : +91-172-2565566

Unit-II :
Hill Top Industrial Estate, Jharmajra EPIP Phase-I, (Extn.),
Bharoli Kalan, Baddi (H P) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272

Unit-III :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

NOTES:

1. The above Un-audited (Provisional) Financial Results for the period ended 31.03.2011 were reviewed by the Audit Committee and taken on record at the Board Meeting held on April 30, 2011.
2. During this Quarter, the Company:
 - a) achieved yet another landmark by receiving the Market Authorization for GEMCITABINE, one of the key products for the treatment of Cancer via de-centralized procedure from Medicine and Healthcare Regulatory Agency (MHRA) U. K. The other countries in the list are Poland, Germany, Slovenia and Portugal for which the same feat has been achieved.
 - b) secured patent for "Sulbactamax" from Mexico and strengthens its presence in South American continent
 - c) becomes first Indian Company to get GMP certification from Saudi Arabia (SFDA) in Oncology & Carbapenem Injectable space.
 - d) First Indian company to receive GCC approval to market its Oncology & Carbapenem range of products in Gulf.
 - e) expanded its innovations basket with "Sulbactamax" Patents from Russia and Ukraine.
3. The Statutory Auditors have carried out Limited Review of the above Un-audited financial results in terms of Clause 41 of the Listing Agreement.
4. During the quarter, The Company allotted 6,00,000 equity shares pursuant to exercise of conversion by the convertible warrants to promoter group company.
5. During the quarter, one investor grievance was received and the same was resolved. No grievance was pending at the end of the quarter.
6. The Company caters to only one segment i. e. "Pharmaceutical Formulations".

For and on behalf of Board of Directors
For VENUS REMEDIES LIMITED



(Pawan Chaudhary)

Chairman & Managing Director

Place : Panchkula
Date : 30.04.2011

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase-1
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manojpur, Ghandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com



Unit-I :
41-52, Industrial Area, Phase-1, PANCHKULA (HRY.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jhatmaji EPIC, PHASE-I, (Extn.),
Rohrukh, Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-III :
VENUS PHARMA GmbH
AM Bahnhof 1-3 D-59368 Witten, Germany